Purpose: Elderly population will comprise a substantial proportion of colorectal cancer (CRC) patients. We examined patients older than 80 years according to their clinical and pathological characteristics to fully understand the elderly patients.

Methods: CRC patients, 60 years or older at diagnosis, admitted between 2009 and 2014 at our hospital were enrolled. The patients were divided into 2 groups: elderly (aged > 80 years, n = 133), and controls (aged 60 to 79 years, n = 596). Patient’s demographics, risk factors for prognosis of CRC, Clinicopathological parameters, treatment, and survival rates were compared.

Results: The mean ages were 83.9 and 64.8 years, respectively. Male-to-female ratio and tumor sidedness were comparable in both groups. Prognostic factors found in univariate analysis; differentiation, stage, lymphovascular invasion, and carcinoembryonic antigen showed no statistical difference. The microsatellite instability status and number of retrieved lymph nodes were also similar (17.2 vs 21.6, P = 0.505). A significant difference was found in the treatment approach for chemotherapy as the elderly patients with stage III and IV tend to have omitted adjuvant (43.6% vs. 92.8%, P < 0.001) or palliative (35.8% vs. 89.4%, P = 0.016) chemotherapy. Except in stage I, elderly patients showed significantly lower overall survival rates.

Conclusion: Current study shows far-elderly patients with CRC were less likely to receive standard treatments, which might have resulted in an inferior outcome. As the number of elderly patients with CRC increase, our results provide a basis for further clinical and molecular investigations of elderly CRC patients.

Keywords: 80 and over aged; Colorectal neoplasms; Survival
rise, a more comprehensive understanding of the impact of increasing age on clinical and pathological parameters is essential. Therefore, we examined patients older than 80 years according to their clinical and pathological characteristics including survival rates to fully understand the increasing population of elderly patients with CRC.

METHODS

This study was a retrospective, single-center cohort study. The study population included consecutive patients with CRC who were 60 years old or older at diagnosis, who had undergone curative resection for primary CRC between 2009 and 2014 at Ajou University Hospital (Suwon, Korea). For the patients with stage-IV CRC, additional local treatment such as surgical resection or radiofrequency ablation for metastatic lesion was recommended. As a large number of elderly patients with rectal cancer did not receive neoadjuvant chemoradiation, patients with middle-to-low rectal cancers were excluded from the study. The patients were divided into 2 groups: elderly (aged > 80 years, n = 133), and controls (aged 60 to 79 years, n = 596). Medical records of all the patients were retrieved from the database of Ajou University Colon Cancer Center and were reviewed with regard to patients’ demographics, risk factors for the prognosis of CRC, Clinicopathological parameters, treatment given, complications, and survival rates. The data between the 2 groups were compared.

This retrospective study protocol was approved by the Institutional Review Board of Ajou University Hospital (No. AJIRB-MED-MDB-19-447) and written informed consents were waived.

Statistical analysis

Fischer exact test was used to analyze dichotomous variables and the chi-square test was used for variables with more than 2 categories. Statistical analysis was performed using SAS ver. 9.4 (SAS Institute, Cary, NC, USA). The overall survival (OS) rate was assessed by Kaplan-Meier survival analysis, with the log-rank test. Cancer-specific survival and disease-free survival (DFS) rates were assessed using the Cox proportional hazards model, with the Fine and Gray correction for non-cancer-related deaths as a competing risk. Cox proportional hazard models were also applied for multivariate analysis and hazard ratio (HR) estimation. Two-sided P values less than 0.05 were considered statistically significant.

RESULTS

Patient and tumor characteristics

The mean ages of the patients in the elderly and control groups were 83.9 and 64.8 years, respectively. The male-to-female ratios in the elderly and control groups were not similar (42.1%:57.9% vs. 59.6%:40.7%, P = 0.842) (Table 1). The pathological characteristics of the 2 groups are presented in Table 2. The rectal cancer incidence was significantly higher in the control group (52.3% vs. 27.8%, P = 0.017). Except for the upper rectal cancer, tumor sidedness was similar in other cancers. Mucinous carcinoma was also more common in the control group (6.7% vs. 2.3%, P = 0.015). Other features, such as tumor stage, differentiation, and microsatellite instability (MSI) status were not statistically significant.

Treatment

It was probable that radical surgery was performed sparingly in elderly patients. Therefore, we measured the average numbers of retrieved lymph nodes. The average numbers of retrieved lymph nodes were similar in both groups (17.2 vs. 21.6, P = 0.505). There was no significant difference found in the adequacy of lymph node dissection (specimens containing 12 or more nodes). However, significant differences were found in the treatment approach for chemotherapy. Elderly patients with stage-III CRC were less likely to receive adjuvant treatment (43.3% vs. 92.8%, P < 0.001). This was also true for treatment of stage-IV cancer; among the elderly, only 35.8% received palliative chemotherapy, as compared to 89.4%, in the control group (P = 0.016). Additionally, elderly patients underwent local treatment for metastatic sites (surgery or radiofrequency ablation) less frequently (3.4% vs. 75.5%, P < 0.001).

Outcome

The median follow-up time was 65.8 months (range, 41.0 to 88.4

| Table 1. Comparison of patients’ characteristics between the elderly and the control group |
|-----------------------------------|-----------------|-----------------|----------|
| Characteristic                   | Elderly (n = 133) | Control (n = 596) | P-value  |
| Age (yr)                         | 83.9 ± 3.03      | 64.8 ± 5.47      | <0.001   |
| Sex                              |                 |                 | 0.842    |
| Male                             | 56 (42.1)        | 355 (59.6)       |          |
| Female                           | 77 (57.9)        | 241 (40.7)       |          |
| ASA PS classification            |                 |                 | 0.001    |
| I                                | 88 (66.2)        | 477 (80.0)       |          |
| II                               | 35 (26.3)        | 97 (16.3)        |          |
| III                              | 10 (7.5)         | 22 (3.7)         |          |
| Comorbidity                      |                 |                 | 0.015    |
| No abnormality in major organs   | 22 (16.5)        | 256 (43.0)       |          |
| Abnormality in one organ         | 67 (50.4)        | 244 (40.9)       |          |
| Abnormality in more than one organ| 44 (33.1)       | 96 (16.1)        |          |
| Preoperative CEA (ng/mL)         |                 |                 | 0.372    |
| <5                               | 82 (61.7)        | 430 (72.1)       |          |
| ≥5                               | 51 (38.3)        | 166 (27.9)       |          |

Values are presented as mean ± standard deviation or number (%). Elderly group, aged > 80 years; control group, aged 60 to 79 years. ASA, American Society of Anesthesiologists; PS, physical status; CEA, carcinoembryonic antigen.
Table 2. Comparison of pathological features between the elderly and the control group

| Variable                                                                 | Elderly (n = 133) | Control (n = 596) | P-value |
|-------------------------------------------------------------------------|-------------------|-------------------|---------|
| Tumor location                                                          |                   |                   |         |
| Colon                                                                   | 0.017*            | 0.236*            |         |
| Proximal colon cancer                                                   | 43 (32.3)         | 129 (21.6)        |         |
| Distal colon cancer                                                     | 53 (39.8)         | 155 (26.0)        |         |
| Rectum (upper rectum only)                                              | 37 (27.8)         | 312 (52.3)        |         |
| Synchronous or metachronous cancer                                      | 0.725             |                   |         |
| No                                                                      | 124 (93.2)        | 544 (91.3)        |         |
| Yes                                                                     | 9 (6.8)           | 52 (8.7)          |         |
| Differentiation                                                         |                   |                   | 0.184   |
| Well differentiated                                                     | 11 (8.3)          | 82 (13.8)         |         |
| Moderately differentiated                                               | 105 (78.9)        | 430 (72.1)        |         |
| Poorly differentiated                                                   | 13 (9.8)          | 44 (7.4)          |         |
| Mucinous carcinoma                                                      | 4 (3.0)           | 40 (6.7)          | 0.015   |
| MSI status (n = 112 for elderly group)                                   |                   |                   | 0.708   |
| MSS                                                                     | 106 (94.6)        | 542 (90.9)        |         |
| MSI-H                                                                   | 6 (5.4)           | 31 (5.2)          |         |
| MSI-L                                                                   | 0 (0)             | 23 (3.9)          |         |
| MSI test (–)                                                           | 21                | 0                 |         |
| Lymphovascular or perineural invasion                                   | 91 (68.4)         | 337 (56.5)        | 0.376   |
| Retrieved lymph nodes                                                   |                   |                   |         |
| ≥ 12                                                                   | 110 (82.7)        | 494 (82.9)        |         |
| < 12                                                                   | 23 (17.3)         | 102 (17.1)        |         |
| Tumor depthc                                                           |                   |                   | 0.229   |
| T1                                                                     | 9 (6.8)           | 37 (6.2)          |         |
| T2                                                                     | 15 (11.3)         | 67 (11.2)         |         |
| T3                                                                     | 89 (66.9)         | 439 (73.7)        |         |
| T4                                                                     | 20 (15.0)         | 53 (8.9)          |         |
| Lymph nodes metastasisd                                                 |                   |                   | 0.490   |
| N0                                                                     | 70 (52.6)         | 302 (50.7)        |         |
| N1                                                                     | 37 (27.8)         | 162 (27.2)        |         |
| N2                                                                     | 26 (19.5)         | 132 (22.1)        |         |

Values are presented as number (%) or mean ± standard deviation. Elderly group, aged > 80 years; control group, aged 60 to 79 years. Proximal colon cancer, tumor located from cecum to just proximal to splenic flexure; distal colon cancer, tumor located distal to splenic flexure; MSI, microsatellite instability; MSS, microsatellite stability; MSI-H, high-frequency MSI; MSI-L, low-frequency MSI.

*Colon vs. rectum. †Proximal vs. distal colon cancer. ‡Tumor invasion and pathologic stage were classified according to the criteria of the American Joint Committee on Cancer. Tumor invasion was classified as follows: T1, tumor invading submucosa; T2, tumor invading muscularis propria; T3, tumor invading through the muscularis propria; and T4, tumor invading other organs or perforating the visceral peritoneum. Regional lymph nodes metastasis was classified as follows: N0, no regional lymph node metastasis; N1, metastasis in 1 to 3 regional lymph nodes; N2, metastasis in 4 or more regional lymph nodes.

Table 3. Comparison of 5-year overall survival between the elderly and the control group

| CRC stage | Elderly (n = 133) 5-Year overall survival (%) | Control (n = 596) 5-Year overall survival (%) | P-value |
|-----------|-----------------------------------------------|-----------------------------------------------|---------|
| Total     | 66.6                                          | 78.4                                          | 0.005   |
| Stage I   | 80.9                                          | 97.4                                          | 0.551   |
| Stage II  | 73.3                                          | 90.8                                          | 0.012   |
| Stage III | 49.0                                          | 81.0                                          | 0.002   |
| Stage IV  | 20.0                                          | 41.3                                          | 0.007   |

Elderly group, aged > 80 years; control group, aged 60 to 79 years. CRC, colorectal cancer.

Table 4. Comparison of 5-year disease-free survival between the elderly and the control group

| CRC stage | Elderly (n = 133) 5-Year overall survival (%) | Control (n = 596) 5-Year overall survival (%) | P-value |
|-----------|-----------------------------------------------|-----------------------------------------------|---------|
| Total     | 63.0                                          | 74.9                                          | 0.001   |
| Stage I   | 91.3                                          | 96.5                                          | 0.450   |
| Stage II  | 70.7                                          | 85.6                                          | 0.010   |
| Stage III | 46.6                                          | 77.9                                          | 0.001   |
| Stage IV  | 9.6                                           | 38.8                                          | 0.014   |

Elderly group, aged > 80 years; control group, aged 60 to 79 years. CRC, colorectal cancer.

DISCUSSION

Average life expectancy in developed countries is reaching 90 years. Despite the growth of the elderly population, current literature does not describe the unique characteristics or clinical management of this subpopulation. Data regarding very elderly patients, such as nonagenarians, are even rarer. In this study, we observed that increasing age was generally associated with worse
outcomes. Previous studies have suggested that the survival rates of elderly CRC patients may be worse than those of younger patients. The poorer outcomes in elderly patients were understood to be related to higher rates of morbidity and mortality, and repeated hospitalization after surgery [7]. However, other studies have implied similar survival rates between elderly and younger patients [3]. Irvin [8] reported that after correction for the patient’s age, survival rates were similar between old and young patients. Therefore, it can be concluded that the age is a confounding factor for the prognosis of CRC. Patel et al. [11] demonstrated that older age was associated with alterations in clinical and pathological characteristics and lower survival rates. They also suggested that colon cancer phenotype and the efficacy of colon cancer treatments might be dependent on the age. The results of these contradictory papers were the reason to perform this study.

A correlation between age at onset and tumor sidedness has

---

**Fig. 1.** Five-year survival analysis in the elderly and control group with colorectal cancer. (A) Overall survival (P=0.005). (B) Disease-free survival (P=0.001). (C) Disease-free survival, stage I (P=0.450). (D) Disease-free survival, stage II (P=0.010). (E) Disease-free survival, stage III (P=0.001). (F) Disease-free survival, stage IV (P=0.014).
been reported, albeit inconsistently [11]. It is likely that there is a tendency for tumor location to shift from left to right with increasing age. The exact reason for this shift remains unclear. Conflicting results have been reported with regard to prognosis and tumor sidedness. A recent investigation from Mayo Clinic revealed that the prognosis of CRC is significantly related to tumor location; rectal cancer had the best outcome, followed by left side cancer, and right-sided cancer had the worst [12]. Although it was a single-center study, more than 20,000 patients had been observed for 4 decades. In the present study, overall tumor sidedness was not a prominent predictive factor for colon cancer. However, the incidence of rectal cancer was significantly lower in octogenarian and nonagenarians. We suggest that the relative infrequency of rectal cancer might have contributed to the poor prognosis in elderly patients. In the present study, there was no difference in the incidence of MSI in the cancer tissue between elderly patients and the control group. As tumor sidedness was not different between the groups, this result was not unexpected. Some researchers from the Western hemisphere have reported that octogenarians have a clear predilection for right-sided colon cancers [13-15]. This finding might suggest a distinct pathogenesis of CRC among older patients, such as a higher rate of mismatch repair protein deficiency or its phenotype, high-frequency MSI tu-

### Table 5. Univariate analysis of prognostic factors for 5-year overall survival (OS)

| Variable                          | Elderly | Control |
|-----------------------------------|---------|---------|
|                                   | 5-Year OS (%) | P-value | 5-Year OS (%) | P-value |
| Sex                               | 0.457   | 0.652   |
| Male                              | 50.0    | 83.6    |
| Female                            | 83.1    | 81.4    |
| MSI status                         | 0.146   | 0.551   |
| MSS                                | 44.7    | 82.6    |
| MSI-H                             | 100     | 87.0    |
| MSI-L                             | 52.6    | 79.9    |
| Synchronous or metachronous cancer| 0.133   | 0.229   |
| No                                | 66.2    | 82.5    |
| Yes                               | 67.0    | 84.8    |
| Tumor location                    | 0.666   | 0.534   |
| Proximal colon cancer             | 70.8    | 79.8    |
| Distal colon cancer               | 72.3    | 78.3    |
| Rectum                            | 73.1    | 85.0    |
| Differentiation                   | <0.001  | <0.001  |
| Well differentiated               | 71.1    | 94.5    |
| Moderately differentiated          | 60.2    | 82.8    |
| Poorly differentiated              | 45.3    | 62.8    |
| Mucinous carcinoma                | 0.862   | 0.857   |
| No                                | 60.3    | 82.8    |
| Yes                               | 69.9    | 80.3    |
| Lymphovascular invasion           | 0.001   | 0.001   |
| No                                | 71.8    | 89.0    |
| Yes                               | 58.1    | 77.3    |
| Retrieved lymph nodes             | 0.757   | 0.650   |
| ≥12                               | 64.1    | 83.6    |
| <12                               | 50.0    | 78.4    |
| Pathologic stage                  | <0.001  | <0.001  |
| I                                 | 86.3    | 97.4    |
| II                                | 86.6    | 90.8    |
| III                               | 58.8    | 81.0    |
| IV                                | 42.8    | 41.3    |
| Preoperative CEA (ng/mL)           | 0.001   | 0.001   |
| <5                                | 58.2    | 88.6    |
| ≥5                                | 62.9    | 69.1    |

Elderly group, aged > 80 years; control group, aged 60 to 79 years.

MSI, microsatellite instability; MSS, microsatellite stability; MSI-H, high-frequency MSI; MSI-L, low-frequency MSI; synchronous cancer, 2 or more colorectal cancers (CRC) were diagnosed at the time of initial treatments; metachronous cancer, any recurrent primary CRC diagnosed at least 6 months after initial treatments; proximal colon cancer, tumor located from cecum to just proximal to splenic flexure; distal colon cancer, tumor located distal to splenic flexure; CEA, carcinoembryonic antigen.

### Table 6. Cox multivariate proportional regression analysis of prognostic factors on 5-year overall survival rates

| Variable                          | Hazard ratio | 95% confidence interval | P-value |
|-----------------------------------|--------------|-------------------------|---------|
| Age group                         |              |                         |         |
| Control (60–79 yr)                | 1.000        |                         |         |
| Elderly (>80 yr)                  | 1.426        | 1.116–1.627             | 0.001   |
| Differentiation                   |              |                         |         |
| Well differentiated               | 1.000        |                         |         |
| Moderately differentiated          | 2.373        | 0.573–9.830             | 0.233   |
| Poorly differentiated              | 8.604        | 1.927–38.420            | 0.005   |
| Lymphovascular or perineural invasion |            |                         |         |
| No                                | 1.000        |                         |         |
| Yes                               | 1.541        | 0.833–2.851             | 0.168   |
| Pathologic stage                  |              |                         |         |
| I                                 | 1.000        |                         |         |
| II                                | 2.509        | 0.316–19.900            | 0.384   |
| III                               | 3.829        | 0.498–29.442            | 0.197   |
| IV                                | 20.273       | 2.566–160.147           | 0.004   |
| Preoperative CEA (ng/mL)           |              |                         |         |
| <5                                | 1.000        |                         |         |
| ≥5                                | 1.715        | 0.980–3.000             | 0.059   |

CEA, carcinoembryonic antigen.
mors. We could not conclude whether the discrepancy between our results and those of others was because of ethnic differences or the limited number of study patients.

Studies regarding elderly CRC patients showed conflicting results in terms of treatment outcomes. Widdison et al. [16] could not demonstrate a survival rate difference between elderly and younger patients, whereas Mulcahy et al. [3] demonstrated better outcomes in elderly patients. Investigators including McMillan et al. [17] showed poorer outcomes in elderly patients. Since the elderly patients had more comorbidities than the control group, the OS rate could be affected by associated diseases. Therefore, analysis of DFS is more appropriate in this kind of cohort study. Our results show that treatment outcomes in elderly patients were poorer in both the OS and DFS.

As the mainstay of curative CRC treatment remains surgical resection, poorer treatment outcomes in the elderly patients might be because of a less aggressive surgical approach. As shown in Table 1, elderly patients in this study showed poorer general physical condition and more comorbidities than the control group. It is probable that the approach in most patients with poor health may be less aggressive. Dutch researchers have reported a significantly low number of harvested lymph nodes in specimens from elderly patients [18]. Numbers of harvested regional lymph nodes are considered a surrogate marker of radicality of surgery in CRC. In this study, however, the average numbers of harvested nodes were similar between the groups. Therefore, the surgical extents could not be an explanation for the poorer outcome in elderly patients. In addition to radical surgery, chemotherapy is also mainstay of treatment for metastatic CRC and standard adjuvant treatment for stage-III CRC. In concordance with previous studies, the majority of elderly patients in the present study were less likely to receive chemotherapy for both metastasis and adjuvant therapy [10]. The chemotherapy omission rate in elderly patients was not clearly demonstrated. Landrum et al. [19] reported that among patients who did not receive chemotherapy for stage-III CRC, 58% had declined chemotherapy. Patients older than 80 years have been excluded from almost all clinical trials regarding chemotherapy. In our study, only 13.4% of stage-III CRC and 14.2% of stage-IV CRC cases were treated with chemotherapy in the elderly patients [20]. The exact reasons for the omission of chemotherapy were not explored in our study. Multiple reasons have been suggested to account for this phenomenon, including the presence of comorbidities, history of prior malignancies, lack of awareness regarding chemotherapy, and skepticism of the caregivers and the patient’s family regarding the ability of elderly patients to tolerate the therapy. However, this factor could be a possible explanation for a poorer outcome.

The outcome disparity between the elderly and the control group was also found in patients with stage-II CRC. Almost all patients in this stage did not receive adjuvant chemotherapy. The 5-year DFS of patients with stage-II CRC was 70.7% in the elderly, and 85.6% in the control group. Earlier studies suggested that elderly patients having multiple comorbidities, postoperative complications, and multiple readmissions might have higher survival rates [7]. However, in our study, we found the 30-day mortality rates to be similar between the 2 groups and that the difference between OS and DFS was small. We conclude that poorer outcomes in elderly patients are not simply a result of patient comorbidities or postoperative complications, and that cancer possibly recurs because of differences in tumor characteristics.

Analysis of the prognostic factors failed to identify differences between the elderly and control groups. In both groups, cellular differentiation, lymphovascular invasion, preoperative CEA, and cancer stage proved to be the meaningful factors in univariate analysis. These results were similar to previously reported results. Multivariate analysis regarding the entire study population showed that pathologic stage and poor differentiation of tumor cell were the 2 strongest prognostic factors in both groups. Current retrospective study shows far-elderly patients with CRC tend to undergo standard treatment less frequently than the control group. And their OS and DFS were inferior compared to the control group. As the number of elderly patients with CRC continues to increase, our results provide a basis for further clinical and molecular biological investigations of elderly CRC patients.

Limitations of this study include the retrospective methodology that may have caused bias because of unknown or unrecorded confounders. As this is a single-center study, it is more vulnerable to such bias. In addition, the small number of patients enrolled with CRC treated at our center might not have been sufficient. As with other reports, the majority of patients with stage-III and stage-IV CRC were under-treated with chemotherapy. This might explain the bias. However, a surgical bias was not noted in this study. Previous studies have reported significantly lower numbers of retrieved lymph nodes examined and a decreased rate of lymph node positivity in elderly patients. These may have been the reason for conflicting results between cancer stages.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. National Cancer Institute. Surveillance Epidemiology and End Results Program. Cancer stat facts: colorectal cancer. Bethesda (MD): National Cancer Institute; c2019 [cited 2019 Nov 12]. Available from: https://seer.cancer.gov/statfacts/html/colorect.html.
2. Christensen K, Dobhammer G, Rau R, Vauel JW. Ageing populations: the challenges ahead. Lancet 2009;374:1196-208.
3. Mulcahy HE, Patchett SE, Daly L, O’Donoghue DP. Prognosis of elderly patients with large bowel cancer. Br J Surg 1994;81:736-8.
4. Fukuchi M, Ishibashi K, Tajima Y, Okada N, Yokoyama M, Chika...
N, et al. Oxaliplatin-based chemotherapy in patients aged 75 years or older with metastatic colorectal cancer. Anticancer Res 2013;33:4627-30.

5. Berretta M, Aprile G, Nasti G, Urbani M, Bearz A, Lutrino S, et al. Oxaliplatin and capecitabine (XELOX) based chemotherapy in the treatment of metastatic colorectal cancer: the right choice in elderly patients. Anticancer Agents Med Chem 2013;13:1344-53.

6. Grande C, Quintero G, Candamio S, Paris Bouzas L, Villanueva MJ, Campos B, et al. Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer. J Geriatr Oncol 2013;4:114-21.

7. Kunitake H, Zingmond DS, Ryoo J, Ko CY. Caring for octogenarian and nonagenarian patients with colorectal cancer: what should our standards and expectations be? Dis Colon Rectum 2010;53:735-43.

8. Irvin TT. Prognosis of colorectal cancer in the elderly. Br J Surg 1988;75:419-21.

9. Goldvaser H, Katz Shroitman N, Ben-Aharon I, Purim O, Kundel Y, Shepshelovich D, et al. Octogenarian patients with colorectal cancer: characterizing an emerging clinical entity. World J Gastroenterol 2017;23:1387-96.

10. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061-7.

11. Patel SS, Nelson R, Sanchez J, Lee W, Uyeno L, Garcia-Aguilar J, et al. Elderly patients with colorectal cancer have unique tumor characteristics and poor survival. Cancer 2013;119:739-47.

12. Wang CB, Shahjehan F, Merchea A, Li Z, Bekaii-Saab TS, Grothey A, et al. Impact of tumor location and variables associated with overall survival in patients with colorectal cancer: a Mayo Clinic colon and rectal cancer registry study. Front Oncol 2019;9:76.

13. Nojadeh JN, Behrouz Sharif S, Sakhinia E. Microsatellite instability in colorectal cancer. EXCLI J 2018;17:159-68.

14. Benatti P, Gafa R, Barana D, Marino M, Scarselli A, Pedroni M, et al. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res 2005;11:8332-40.

15. Vilar E, Gruber SB. Microsatellite instability in colorectal cancer—the stable evidence. Nat Rev Clin Oncol 2010;7:153-62.

16. Widdison AL, Barnett SW, Betambeau N. The impact of age on outcome after surgery for colorectal adenocarcinoma. Ann R Coll Surg Engl 2011;93:445-50.

17. McMillan DC, Hole DJ, McArdle CS. The impact of old age on cancer-specific and non-cancer-related survival following elective potentially curative surgery for Dukes A/B colorectal cancer. Br J Cancer 2008;99:1046-9.

18. Kim YJ. Colorectal cancer surgery in elderly patients. Ann Coloproctol 2017;33:121-2.

19. Landrum MB, Keating NL, Lamont EB, Bozeman SR, McNeil BJ. Reasons for underuse of recommended therapies for colorectal and lung cancer in the Veterans Health Administration. Cancer 2012;118:3345-55.

20. Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003;21:1383-9.